• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

A not-for-profit health and tax policy research organization.

  • Home
  • About Us
    • Mission and History
    • Officers and Trustees
    • Scholars and Staff
    • Who was Galen?
  • Activities
    • Core Activities
    • State Leaders Calls
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Donate
  • Contact Us
  • Major Papers
  • Broadcast Interviews

CMS Rule On Biosimilar Payment Could Have Serious Side Effects

POSTED BY Grace-Marie Turner and Roland (Guy) King | Forbes on November 17, 2015.

The Obama administration and leading members of Congress are clashing over a new Medicare payment rule that could compromise patient care, impede development of a fledgling part of the biologics industry, and make it more difficult to track patient safety issues.

At issue is government payment policy for a new class of drugs called “biosimilars”—drugs that are similar but not identical to the original brand name biologic drug.

Biologics are complex large-molecule proteins created in the laboratory but derived from living organisms. These molecules function within the body’s own biological processes to treat cancer, diabetes, rheumatoid arthritis, and other diseases. Biosimilars are reverse-engineered proteins with unique manufacturing recipes and are developed to mimic the effect of the original biologic in patients.

However, the physical attributes of the biosimilar drug will never be exactly the same as of the original biologic or any other biosimilar drug. Each biologic drug has its own unique biochemical signature, and this diversity can potentially impact effectiveness and side effects for patients.

The Centers for Medicare and Medicaid Services (CMS) finalized a rule October 30 explaining how Medicare will pay for physician-administered biosimilar drugs. It decided to dump all biosimilars that mimic the same original brand name biologic into the same category. This is identical to the way it treats cheap generic pills which, unlike biosimilars, can be mass-produced as exact chemical copies.

Continue Reading…

Filed Under: Medicare

Primary Sidebar

NEW – OF INTEREST

Health Care Choices 20/20:

A Vision for the Future


See the latest interview of Grace-Marie Turner on C-SPAN

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • The Daily Signal
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute, Inc © 2021; · Log in